Sign up to save your podcasts
Or
Share Jonathan I. Silverberg, MD, PhD, MPH / Eric Simpson, MD, MCR - Advancing Care for People Living With Moderate to Severe Atopic Dermatitis: The Future Looks Clear
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Jonathan I. Silverberg, MD, PhD, MPH / Eric Simpson, MD, MCR - Advancing Care for People Living With Moderate to Severe Atopic Dermatitis: The Future Looks Clear
Go online to PeerView.com/KCX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Over the past decade, the understanding of atopic dermatitis (AD) pathogenesis has evolved, giving way to numerous potential therapeutic targets. During this time, Janus kinase (JAK) inhibitors—a new class of medications—have also emerged. While the JAK-signal transducer and activator of transcription (JAK-STAT) pathway did not seem to be an obvious target early on, JAK inhibitors are likely to be the next generation of agents FDA approved for the treatment of moderate to severe AD. Indeed, JAK inhibitors are demonstrating benefit across multiple dermatologic diseases and constitute a promising frontier for dermatologic therapy overall. In this activity, based on a recent live web broadcast, our expert faculty examine the complex pathogenesis that underlies AD, focusing on the rationale for development of novel therapeutic approaches. In addition, key information (eg, mechanism of action, side-effect profiles, and dosing) for these new and emerging agents for moderate to severe AD will be provided, as well as the most up-to-date efficacy and safety data and practical considerations for clinical use. Upon completion of this accredited CE activity, participants should be better able to: Recognize recent insights into the pathogenesis of atopic dermatitis (AD) that have led to the development of new molecules targeting key cytokine signaling pathways, Evaluate recent safety and efficacy data related to emerging treatment options for moderate to severe AD, identifying potential implications for patient care, Develop strategies to identify candidates for newer therapeutic options and overcome barriers to achieving treatment goals in patients with moderate to severe AD.
View all episodes
By PVI, PeerView Institute for Medical Education
3.5
2727 ratings
Go online to PeerView.com/KCX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Over the past decade, the understanding of atopic dermatitis (AD) pathogenesis has evolved, giving way to numerous potential therapeutic targets. During this time, Janus kinase (JAK) inhibitors—a new class of medications—have also emerged. While the JAK-signal transducer and activator of transcription (JAK-STAT) pathway did not seem to be an obvious target early on, JAK inhibitors are likely to be the next generation of agents FDA approved for the treatment of moderate to severe AD. Indeed, JAK inhibitors are demonstrating benefit across multiple dermatologic diseases and constitute a promising frontier for dermatologic therapy overall. In this activity, based on a recent live web broadcast, our expert faculty examine the complex pathogenesis that underlies AD, focusing on the rationale for development of novel therapeutic approaches. In addition, key information (eg, mechanism of action, side-effect profiles, and dosing) for these new and emerging agents for moderate to severe AD will be provided, as well as the most up-to-date efficacy and safety data and practical considerations for clinical use. Upon completion of this accredited CE activity, participants should be better able to: Recognize recent insights into the pathogenesis of atopic dermatitis (AD) that have led to the development of new molecules targeting key cytokine signaling pathways, Evaluate recent safety and efficacy data related to emerging treatment options for moderate to severe AD, identifying potential implications for patient care, Develop strategies to identify candidates for newer therapeutic options and overcome barriers to achieving treatment goals in patients with moderate to severe AD.
More shows like PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
View all
EMCrit FOAM Feed
1,865 Listeners
JAMA Editors' Summary
135 Listeners
AFP: American Family Physician Podcast
694 Listeners
JAMA Clinical Reviews
496 Listeners
Diabetes Core Update
101 Listeners
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast
10 Listeners
PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
10 Listeners
PeerView Gastroenterology CME/CNE/CPE Video Podcast
4 Listeners
PeerView Internal Medicine CME/CNE/CPE Video Podcast
2 Listeners
PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast
5 Listeners
PeerView Endocrinology & Diabetes CME/CNE/CPE Video Podcast
2 Listeners
PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
3 Listeners
PeerView Infectious Diseases CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
2 Listeners
PeerView Infectious Diseases CME/CNE/CPE Video Podcast
0 Listeners
PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
9 Listeners
PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
2 Listeners
PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
11 Listeners
PeerView Clinical Pharmacology CME/CNE/CPE Video
2 Listeners
PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
4 Listeners
PeerView Gastroenterology CME/CNE/CPE Audio Podcast
3 Listeners
PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast
5 Listeners
Mayo Clinic Talks
291 Listeners
Frankly Speaking About Family Medicine
260 Listeners
The Curbsiders Internal Medicine Podcast
3,331 Listeners
The Daily
112,586 Listeners
Core IM | Internal Medicine Podcast
1,153 Listeners
Real Life Pharmacology - Pharmacology Education for Health Care Professionals
712 Listeners
Primary Care Knowledge Boost
50 Listeners
Run the List
252 Listeners
The Curious Clinicians
369 Listeners
The Cribsiders
314 Listeners